Andrew B Lassman MD , MS, FAAN

Neurology•New York, NY

Neurooncology

Neuro-Oncology Division Chief, Associate Dean of Clinical Trials

Request Appointment

710 West 168th StreetNew York, NY 10032
Book by Phone+1(231) 787-0810

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2001 - 2003
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 1997 - 1998
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997, MD

Certifications & Licensure

NJ State Medical License 2022 - 2027
NY State Medical License 1998 - 2027
CT State Medical License 2023 - 2026
KS State Medical License 2021 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly
America's Top Doctors Castle Connolly
Top Doctors: New York Metro Area Castle Connolly
America's Top Doctors for Cancer Castle Connolly
Join now to see all

Clinical Trials

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Start of enrollment: 2007 Jan 24
Completed
Phase 2
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Start of enrollment: 2007 Jun 01
Completed
Phase 2
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Completed
Phase 2
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas Start of enrollment: 2011 Jan 07
Completed
Phase 1
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2013 Jul 18
Completed
Phase 1, Phase 2
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma Start of enrollment: 2014 Jan 09
Terminated
Phase 1, Phase 2
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Start of enrollment: 2013 Nov 27
Completed
Phase 2
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Start of enrollment: 2013 Dec 09
Completed
Phase 2
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas Start of enrollment: 2014 Mar 03
Terminated
Phase 2
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Start of enrollment: 2014 Dec 08
Completed
Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects Start of enrollment: 2017 Dec 06
RECRUITING
PHASE1, PHASE2
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Start of enrollment: 2020 Sep 01
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2020 Jun 08
TERMINATED
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
Jaishri Blakeley, Nimish A Mohile, Hans Messersmith, Andrew B Lassman, David Schiff
Journal of Clinical Oncology. 2025-06-20
1 citations
Pre-radiation targeted therapy for highly selected patients with newly diagnosed glioblastoma: New tricks for an old dog?
Macarena I de la Fuente, Andrew B Lassman
Neuro-Oncology. 2025-05-15
1 citations
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.
Jaishri Blakeley, Nimish A Mohile, Hans Messersmith, Andrew B Lassman, David Schiff
Neuro-Oncology. 2025-04-30

Lectures

Efficacy and safety of selinexor in recurrent glioblastoma.
2019 ASCO Annual Meeting - 6/1/2019
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Brain Cancer: The Latest Advancements on Diagnostics, TreatmentOctober 25th, 2022
Conversation with Anil K. Rustgi, MD, on Visit by Jill Biden and Queen of SpainSeptember 21st, 2022
Promising Treatment for Deadly Brain CancerFebruary 4th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment